Correspondence

Ivermectin for COVID-19: Promising but not yet conclusive

Bookmark and Share
R van Rensburg, E H Decloedt, H Reuter, A Parker, N Schrueder, S Lahri

Abstract


Ivermectin has been proposed as a potential definitive and prophylactic treatment for COVID-19. Ivermectin is an anthelmintic drug that is usually indicated for filarial and resistant scabies infections, but has been shown to have antiviral activity and anti-inflammatory activity in vitro. Ivermectin has the potential to
be a promising directed therapy in the drug armamentarium against
COVID-19, as it has been shown to have in vitro activity against
SARS-CoV-2.


Authors' affiliations

R van Rensburg, Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa

E H Decloedt, Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa

H Reuter, Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa

A Parker, Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa

N Schrueder, Division of General Internal Medicine, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa

S Lahri, Emergency physician, Khayelitsha Hospital; and Division of Emergency Medicine, Department of Family Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

Full Text

PDF (66KB)

Cite this article

South African Medical Journal 0;0(0):.

Article History

Date submitted: 2021-01-12
Date published: 2021-01-12

Article Views

Abstract views: 12010
Full text views: 2497

Comments on this article

*Read our policy for posting comments here